Related Experiment Video
Updated: Jul 9, 2026
07:53
Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter
Published on: April 17, 2026
Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage
1Department of Preclinical and Clinical Pharmacology, University of Florence, Viale Pieraccini 6, 50135 Firenze, Italy. flavio.moroni@unifi.it
Current Opinion in Pharmacology
|November 23, 2007
Summary
Poly(ADP-ribose)polymerases (PARPs) overactivation contributes to brain damage after stroke. Inhibiting PARPs reduces this damage, suggesting they are a therapeutic target for stroke pathology.
Area of Science:
- Biochemistry
- Neuroscience
- Genomics
Background:
- Poly(ADP-ribose)polymerases (PARPs) are enzymes crucial for DNA repair, cell cycle control, and gene expression.
- PARPs are abundant in cell nuclei and play vital roles in maintaining genomic integrity.
- Overactivation of PARPs is implicated in cellular damage.
Purpose of the Study:
- To investigate the role of Poly(ADP-ribose)polymerases (PARPs) in brain damage following ischemia.
- To explore the therapeutic potential of PARP inhibition in stroke models.
Main Methods:
- Utilized PARP-deficient mice and PARP inhibitors in various stroke models.
- Examined the cellular and molecular mechanisms of PARP-mediated cell death in the brain.
Main Results:
- PARP overactivation occurs in multiple brain cell types, including neurons, astrocytes, and microglia, after ischemia.
- PARP inhibition significantly reduces brain damage in experimental stroke models.
- PARP overactivation contributes to cell death through energy depletion, apoptosis-inducing factor translocation, and altered inflammatory mediator expression.
Conclusions:
- Poly(ADP-ribose)polymerases (PARPs) play a critical role in postischemic brain damage.
- Targeting PARPs represents a promising therapeutic strategy for reducing stroke pathology.
Related Concept Videos
01:02Long-patch Base Excision Repair
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
02:36DNA Damage can Stall the Cell Cycle
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
02:36DNA Damage Can Stall the Cell Cycle
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
02:37Restarting Stalled Replication Forks
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart, a...